Desktop Site
|
25 Apr 24 | 16:00
|
Close
Equity
SME
Eq Drv
Currency
Commodity
Corporates
Watch List
Get Quote
*
Notices
|
S&P
BSE SENSEX
74,339.44
+486.50
+0.66 %
Corporate Announcement
Security Code
524804
Company
Aurobindo Pharma Ltd
Exchange Received Time
10/05/2022 21:00:06
Exchange Disseminated Time
10/05/2022 21:00:06
Time Taken
00:00:00
Completion Of US FDA Inspection At Our Unit VII - Reg., |
05/10/22 21:00
Sub: Completion of US FDA Inspection at our Unit VII - Reg., Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that: The United States Food and Drug Administration (US FDA) inspected Company's Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, from 2nd to 10th May 2022. At the end of the inspection, we have been issued a 'Form 483' with six observations. The Company will respond to the US FDA within the stipulated timeline and work closely with US FDA to close the observations.
Attachment
<< Back
Recently Viewed